Instruction for use: Oxymetazoline (Oxymetazolinum)

chemical name 3 - [(4,5-Dihydro-1H-imidazol-2-yl) methyl] -6- (1,1-dimethylethyl) -2,4-dimethylphenol (as hydrochloride)

Pharmacotherapeutic group:

decongestant

Alpha-adrenoceptor agonists

Ophthalmic tools

The nosological classification (ICD-10)

H65 purulent otitis media:

Inflammation of the middle ear, Allergic otitis media

H66.9 Otitis media, unspecified

Chronic otitis, Otitis, otitis media, middle ear infections, Otitis media in children

J00 Acute nasopharyngitis [runny nose]

Viral rhinitis, Inflammation of the nasopharynx, Inflammatory diseases of the nose, purulent rhinitis, Nasal congestion, Nasal congestion with colds and flu, The difficulty of nasal breathing, The difficulty of nasal breathing for colds, Difficulty in nasal breathing, Difficulty in nasal breathing in colds, nasal, hypersecretion, cold, ARI with rhinitis phenomena, coryza, Acute rhinitis of various origins, Acute rhinitis with thick purulent mucous exudate, Acute nasopharyngitis, Swelling of the mucosa of the nasopharynx, Rhinitis, rhinorrhea, Infectious-inflammatory diseases of ENT organs, heavy cold, rhinopharyngitis, nasopharyngitis

J01 Acute sinusitis

Inflammation of the sinuses, Inflammatory diseases of the paranasal sinuses, Purulent inflammation of the paranasal sinuses, Infectious-inflammatory diseases of ENT organs, Infection of the sinuses, Combined sinusitis, Exacerbation of sinusitis, Acute inflammation of the paranasal sinuses, Acute bacterial sinusitis, Acute sinusitis in adults, Subacute sinusitis, acute Sinusitis, sinusitis

J01.9 Acute sinusitis, unspecified

Allergic sinusitis, Pain in sinusitis, Inflammation of the sinuses,catarrhal sinusitis, polypoid sinusitis, Sinusitis, acute sinusitis, genyantritis, purulent sinusitis

J30.0 Vasomotor rhinitis

Rhinitis chronic vasomotor neurovegetative

J30.1 Allergic rhinitis caused by the pollen of plants:

hay fever, Hypersensitivity to pollen, Polypoid allergic rhinosinusitis, Seasonal hay fever, Seasonal rhinitis

J30.3 Other allergic rhinitis

Allergic rhinitis is a year-round, Allergic rhino-conjunctivitis

J999 * Diagnosis of Respiratory Diseases

bronchography, bronchoscopy, Diagnostic procedures in the nasal passages, Diagnostic Study of the bronchi, laryngoscopy, Preparing for rhinoscopy, Preparing the patient for bronchoscopy and / or bronhografii, Preparing the patient for bronchoscopy or bronhografii, Preparing the patient for diagnostic procedures in the nasal passages, Preparing the patient for diagnostic procedures in the area of the nasal passages, rhinoscopy, Visualization of the chest cavity, Chest X-ray, Mediastinoscopy

CodeCAS 1491-59-4

Characteristic

Oxymetazoline hydrochloride is freely soluble in water and alcohol. Practically insoluble in ether, chloroform, benzene. The molecular weight of 296.84.

Pharmacological Properties of Oxymetazoline Pharmachologic effect
vasoconstrictor, antikongestat, alpha-agonists.

It stimulates alpha-adrenergic receptors: at low concentrations has mainly α2-adrenomimeticheskoe action at high operating and α1-adrenoceptors. Narrowing of blood vessels at the site of application. At intranasal application reduces the swelling of the mucous membranes of the upper respiratory tract, facilitates nasal breathing, reduces blood flow to the venous sinuses. When instilled into the conjunctival sac reduces swelling of the conjunctiva. The action begins in 15 minutes after application, duration - 6-8 hours.

For topical application (spray) oxymetazoline undergoes a small extent of systemic absorption, so its concentration in plasma is low. Displayed mostly unchanged in the urine and feces. T1 / 2 of 5-8 days.

Indications for Oxymetazoline
Acute rhinitis (including allergic), vasomotor rhinitis, paranasal sinuses, evstahiit, otitis media; for mucosal vasoconstriction diagnostic purposes (under medical supervision).

Contraindications for Oxymetazoline

Hypersensitivity, including other decongestants for nasal application; atrophic rhinitis, angle-closure glaucoma, hypertension, marked atherosclerosis, cardiac arrhythmias, congestive heart failure, diabetes, hyperthyroidism, children up to 1 year (for drops 0, 025 and 0.05%), children under 6 years (for spray 0.05%).

Pregnancy and breast-feeding

During pregnancy and breastfeeding do not exceed the recommended dosage allowed. Application is possible after careful evaluation of the ratio of benefits to the mother and the risk to the fetus or child.

Side effects

Local reactions: dryness and burning sensation of nasal mucosa, dry mouth or throat, sneezing, "rebound" swelling of the mucous membrane (increased discharge from the nose or nasal congestion).

Systemic effects: insomnia, agitation, increased anxiety, dizziness, headache, palpitations, nausea, increased blood pressure.

Other: tachyphylaxis, reactive hyperemia and atrophy of the mucous membranes of the mucous membranes of the nasal cavity (with prolonged use).

Interaction

It slows the systemic absorption of local anesthetics and prolong their effect. The combined use with other vasoconstrictor drugs increases the risk of side effects. With simultaneous use of oxymetazoline and MAO inhibitors or tricyclic antidepressants may increase blood pressure.

Overdose

Symptoms (after a significant overdose or accidental ingestion): pupillary constriction, nausea, vomiting, cyanosis, fever, tachycardia, arrhythmia, vascular insufficiency, hypertension, respiratory disorders, pulmonary edema, cardiac arrest; In addition, mental disorders can occur, as well as the oppression of the CNS functions accompanied by drowsiness, decrease in body temperature, bradycardia, hypotension, respiratory arrest, and possible development of coma.

Treatment: gastric lavage, activated charcoal, an urgent appeal to the doctor, symptomatic therapy.

Precautionary measures

Children can be improved absorption of oxymetazoline in the blood, leading to the development of side effects.

After prolonged use of cold remedies containing oxymetazoline, in doses exceeding recommended, we can not exclude the overall impact on the cardiovascular system and central nervous system. In these cases, the ability to operate a vehicle or equipment can be reduced.